Your
answer (C) is not the one that we are looking for! (A) is correct!
- The bolus dose of 180 µg/kg of eptifibatide
is appropriate in a patient with an acute coronary syndrome (ACS). However,
the infusion rate has to be cut in half (to 1.0 µg/kg/min)
when the serum creatinine is between 2.0 and 4.0 mg/dL. Patients
weighing more than 121 kg should receive a maximum bolus of 22.6 mg
followed by a maximum infusion rate of 7.5 mg per hour.
- Activation of platelet GP IIb/IIIa receptors result in fibrinogen
binding. This is the final common pathway that triggers platelet aggregation
and platelet mediated thrombosis.
- In patients with ACS (unstable angina and non ST elevation MI) the
composite risk of death, MI and recurrent ischemia has been shown to
be significantly reduced with the use of IIB/IIIA inhibitors (Circulation
100: 2045, 1999)
Currently, the following three IIB/IIIA inhibitors are available in the
US: |